StreetAlpha.app
Home › Stocks › AYTU

Aytu Biopharma, Inc (AYTU)

$2.66
▲ +47.78%
LAST CLOSE · NOV 17

Aytu BioPharma sells prescription medicines for depression, ADHD and allergic conditions from its base in Denver, Colorado. It last closed at $2.66 on Nov 17, up 47.78% on the day. AYTU reports earnings on Tue, Feb 2, 2027. The average 12-month price target from 2 analysts is $8.85 (+232.7% from the last close), with a high of $15.00 and a low of $2.70.

AI Auto Pilots
Is AYTU in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$58.5M
−8.1% vs a year ago
Net income
−$20.1M
−34.3% margin
EPS (diluted)
−$1.28
Gross margin
63.3%
$37.1M gross profit
Valuation
Market cap
$28.9M
10.9M shares
P/E
–
No P/E while losing money
Price to sales
0.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$25.5M
At Sep 30
Debt
$10.5M
At Sep 30
Shareholder equity
$31.6M
Shares outstanding
10.9M
At Nov 9
Fiscal year endsJune
ExchangeNasdaq
Financials history
FY2022: $96.7M$96.7MFY2022FY2023: $107.4M$107.4MFY2023FY2024: $65.2M$65.2MFY2024FY2025: $66.4M$66.4MFY2025FY2026: $57.6M$57.6MFY2026

From AYTU's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Feb 2
2027 · Time not announced
Consensus EPS forecast
-$0.20
$15.3M revenue est.
Year-ago EPS
—
Not on file
Options-implied move
—
Posted about a week before
Analyst consensus
1 Buy · 1 Hold
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy · 1 Hold
2firms
1 Buy1 Hold0 Sell
Only 2 firms rated AYTU in the past 90 days, not enough for a consensus
Average 12-month target
$8.85
▲ 232.7% upside

Based on 2 analysts who set a price target on AYTU in the past 90 days. The average target is $8.85, with a high of $15.00 and a low of $2.70, compared with the last close of $2.66.

Low $2.70Avg $8.85High $15.00
Blue marker: last close $2.66
Highest target$15.00
Average target$8.85
Lowest target$2.70
Latest rating changes
Lake StreetDowngrade
Nov 17Hold$2.70
Ascendiant CapitalTarget raised
Sep 30Buy$14.50 → $15
Ascendiant CapitalMaintained
Jun 11Buy$14.50
DateFirmActionRatingPrice target
Nov 17Lake StreetDowngradeHold$2.70
Sep 30Ascendiant CapitalTarget raisedBuy$14.50 → $15
Jun 11Ascendiant CapitalMaintainedBuy$14.50
Loading…

Technical Analysis

AYTU · as of the Nov 17 close · updated after every close
Turning up, overbought

The stock is 28% above its 20 day and 24% above its 50 day average. It is 15% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 79), overbought. The nearest support is the Pivot S1 at $2.65, and the nearest resistance the Pivot R1 at $2.67.

Short trendBullish
Long trendNeutral
MomentumStrong
StretchOverbought
VolatilityHigh, 6.0%/day
Key levels
$3.0752 week high+15.4%
$2.67Pivot R1+0.4%
$2.66Pivot+0.0%
$2.66Last close
$2.65Pivot S1−0.4%
$2.27200 day average−14.7%
$2.25Swing low (Aug 13)−15.4%
$2.13100 day average−19.9%
$2.0150 day average−24.4%
$1.9220 day average−27.8%
$1.7552 week low−34.2%
Indicators
RSI (14)78.98Overbought above 70Overbought
MACD0.00Above its signal lineBullish
Stochastic42.8Middle of its rangeNeutral
ADX (14)19.0No clear trend
Williams %R-1.1Oversold below −80, overbought above −20Overbought
CCI (20)513.1Oversold below −100, overbought above 100Overbought
Rate of change+37.8%Change over 10 sessionsBullish
ATR (14)$0.16Typical daily range, 6.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for AYTU

What happened before

See how AYTU did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in AYTU in the last 90 days.

Loading…

See today’s whale options flow across the market →

AYTU Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼9 buying vs 14 selling
  • ▼Held by funds -11.1 pts
  • ▼Funds holding -2
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3638−5.3%
In funds' top 1000–
Held by funds34.2%45.3%−11.1 pts
New / increased3 / 63 / 12−40.0%
Reduced / sold out9 / 55 / 2+100.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AYTU institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AYTU is in one of them and how their past AYTU trades turned out.

AYTU in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AYTU in an article yet. Here's the latest on the wider market.

About Aytu Biopharma

Aytu BioPharma is a pharmaceutical company based in Denver, Colorado, that markets and sells prescription medicines for central nervous system conditions. Its main product is EXXUA, a treatment for major depressive disorder in adults. The company also sells ADHD medicines, Adzenys and Cotempla, and Karbinal, an antihistamine suspension used to treat allergic conditions. It sells its products mainly through wholesalers and pharmacies.

Headquarters
Denver, CO